PDF herunterladen
CC BY 4.0 · Rev Bras Ginecol Obstet 2023; 45(11): e689-e698
DOI: 10.1055/s-0043-1772483
Original Article
Oncology

Risk Profile of High-grade Cervical Lesions and Cervical Cancer Considering the Combination of Cytology, HPV Genotype, and Age among Women Undergoing Colposcopy

Perfil de risco de lesões cervicais de alto grau e câncer cervical considerando a combinação de citologia, genótipo do HPV e idade entre mulheres submetidas a colposcopia
Júlio César Possati-Resende 
1   Prevention Department, Hopital do Câncer de Barretos, SP, Brazil.
,
Thais Zilles Fritsch 
2   Research and Education Institute, Hospital do Câncer de Barretos, Barretos, SP, Brazil.
,
Karen Cristina Borba Souza 
2   Research and Education Institute, Hospital do Câncer de Barretos, Barretos, SP, Brazil.
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Objective The present study aims to establish a risk profile for high-grade cervical lesions and cervical cancer (CIN2 + ) in women undergoing colposcopy at the Hospital do Câncer de Barretos, through the analysis of Human Papillomavirus (HPV) infection, cervical cytology, and patient's age.

Methods Retrospective cross-sectional study based on a computerized database of women aged ≥ 18 years old who underwent colposcopy at the Prevention Department of the Hospital do Câncer de Barretos from 2017 to 2019.

Results A total of 3,411 women were included, 58.0% were positive for high-risk-HPV test, with a higher prevalence of CIN2+ for HPV16 (30.3%) and other HPV (45.0%). Cytological findings that suggest invasive cervical cancer (squamous cells or adenocarcinoma), regardless of the status of HPV test, showed 100% diagnosis of CIN2 + , while atypias that suggest high-grade lesions, HSIL and ASC-H, positive for HPV test, showed in 86 and 55.2%, respectively, diagnosis of CIN2 + . ASC-H cytological results among women aged > 40 years old and negative HPV were mainly associated with benign findings. We observed that ≤ CIN1 has a higher prevalence among older women with negative HPV, while for high-grade lesions there is an increase among young women HPV16- and/or 18-positive. In cancer diagnosis, we observed a predominance of HPV 16/18 regardless of the age group.

Conclusion The highest risks of precursor lesions and cervical cancer were found among women with positive HPV 16/18 tests and severe cytological atypia in population screening tests. In addition, cytological findings of ASC-H HPV negative in women > 40 years old usually represent benign findings in histological investigation.

Resumo

Objetivo Estabelecer um perfil de risco de lesões intraepiteliais de alto grau e câncer do colo do útero (NIC2 + ) em mulheres submetidas a colposcopia considerando-se a infecção pelo papilomavírus humano (HPV), citologia cervical e idade.

Métodos Estudo retrospectivo transversal em banco de dados informatizado de mulheres com idade ≥ 18 anos que realizaram colposcopia no departamento de Prevenção de Câncer no Hospital do Câncer de Barretos/SP no período de 2017 a 2019.

Resultados Foram incluídas 3.411 mulheres, sendo 58,0% positivas para HPV de alto risco, e maior prevalência de NIC2+ para HPV16 (30,3%) e outros HPV (45,0%). Resultados citológicos sugestivos de lesões invasivas (epidermoide ou adenocarcinoma), independente do teste de HPV, apresentaram 100% de diagnóstico NIC2 + , enquanto atipias sugestivas de lesões de alto grau, HSIL e ASC-H, associados a HPV positivo, apresentaram 86 e 55,2%, respectivamente. Resultados citológicos de ASC-H entre mulheres > 40 anos e HPV negativo foram associados principalmente a achados benignos. Observamos que ≤ NIC1 apresenta uma maior prevalência entre mulheres mais velhas com HPV negativo, enquanto para lesões de alto grau, há um aumento entre mulheres mais jovens positivas para HPV16/18. Para diagnóstico de câncer, observamos que há um predomínio de HPV16/18 independente da faixa etária.

Conclusão Foi identificado maior risco de lesões precursoras e câncer entre mulheres com HPV 16/18 positivo e atipias citológicas graves em testes de rastreio populacional. Além disso, resultados citológicos de ASC-H quando associados a HPV negativo com idade > 40 anos habitualmente representam achados benignos em investigação histológica.

Keywords

squamous intraepithelial lesions of the cervix - uterine cervical neoplasms - papillomavirus infections - colposcopy - risk

Palavras-chave

lesão escamosa intraepitelial cervical - neoplasias do colo do útero - infecções por papillomavirus - colposcopia - risco

Contributors

All authors were involved in substantial contributions to conception and design, data collection, data analysis and interpretation; article writing, relevant critical review of the intellectual content; and final approval of the version to be published.




Publikationsverlauf

Eingereicht: 27. Februar 2023

Angenommen: 05. Juni 2023

Artikel online veröffentlicht:
29. November 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Global health estimates: Leading causes of death [Internet]. [citado 21 de novembro de 2022]. Disponível em: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
    PubMedGoogle Scholar
  • 3 Estimativa dos casos novos de câncer para 2023 (Brasil) [Internet]. Instituto Nacional de Câncer - INCA. [citado 24 de novembro de 2022]. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa/estado-capital/brasil/brasil-consolidado
    PubMedGoogle Scholar
  • 4 Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590) 890-907
    CrossrefPubMedGoogle Scholar
  • 5 Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019; 393 (10167): 169-182
    CrossrefPubMedGoogle Scholar
  • 6 Bruni L, Serrano B, Albero G. et al. Americas: Human Papillomavirus and Related Diseases Report [Internet]. 22 o ed. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).; 2021 [citado 20 de outubro de 2022]. 167 p. Disponível em: https://hpvcentre.net/statistics/reports/XWX.pdf
    PubMedGoogle Scholar
  • 7 Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. [citado 12 de maio de 2021]. Disponível em: https://www.who.int/publications-detail-redirect/9789240014107
    PubMedGoogle Scholar
  • 8 Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F. et al; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24 (02) 102-131
    CrossrefPubMedGoogle Scholar
  • 9 Godoy LR, Possati-Resende JC, Guimarães YM, Pedrão PG, Dos Reis R, Longatto-Filho A. Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?. Cancers (Basel) 2022; 14 (11) 13
    CrossrefPubMedGoogle Scholar
  • 10 Instituto Nacional de Câncer José Alencar Gomes da Silva. Diretrizes brasileiras para o rastreamento do câncer do colo do útero [Internet]. INCA - Instituto Nacional de Câncer. 2018 [citado 21 de novembro de 2022]. Disponível em: https://www.inca.gov.br/publicacoes/livros/diretrizes-brasileiras-para-o-rastreamento-do-cancer-do-colo-do-utero
    PubMedGoogle Scholar
  • 11 Possati-Resende JC, Vazquez FL, Biot ST, Mauad EC, Talarico T, Fregnani JHTG. et al. Organized Cervical Cancer Screening Program in Barretos, Brazil: Experience in 18 Municipalities of São Paulo State. Acta Cytol 2018; 62 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 12 Teixeira JC, Vale DB, Campos CS, Bragança JF, Discacciati MG, Zeferino LC. Organization of cervical cancer screening with DNA-HPV testing impact on early-stage cancer detection: a population-based demonstration study in a Brazilian city. Lancet Reg Health Am 2021; 5: 100084
    PubMedGoogle Scholar
  • 13 Aydın S, Öncü HN, Arıcı DS. Diagnostic performance of immediate colposcopy among women with high-risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology. J Obstet Gynaecol Res 2021; 47 (02) 720-725
    CrossrefPubMedGoogle Scholar
  • 14 Yalcin I, Sari ME, Sahin H, Gultekin M, Gungor T, Meydanli MM. Colposcopic biopsy findings among women with either HPV-16 only or HPV-18 only who have normal cervical cytology. Int J Gynaecol Obstet 2018; 143 (03) 300-305
    CrossrefPubMedGoogle Scholar
  • 15 Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap P-S. et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol 2015; 137 (01) 47-54
    CrossrefPubMedGoogle Scholar
  • 16 Correa RM, Baena A, Valls J, Colucci MC, Mendoza L, Rol M. et al; ESTAMPA Study Group. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One 2022; 17 (07) e0272205
    CrossrefPubMedGoogle Scholar
  • 17 Tidy JA, Lyon R, Ellis K, Macdonald M, Palmer JE. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study. BJOG 2020; 127 (10) 1260-1267
    CrossrefPubMedGoogle Scholar
  • 18 Del Pino M, Angeles MA, Martí C, Henere C, Munmany M, Marimon L. et al. Colposcopic Impression Has a Key Role in the Estimation of the Risk of HSIL/CIN3. Cancers (Basel) 2021; 13 (06) 1224
    CrossrefPubMedGoogle Scholar
  • 19 Zhong G, Wang Y, Xie Q, Lin R, Yao T. HPV-specific risk assessment of cervical cytological abnormalities. BMC Cancer 2021; 21 (01) 949
    CrossrefPubMedGoogle Scholar
  • 20 Safaeian M, Wright Jr TC, Stoler MH, Ranger-Moore J, Rehm S, Aslam S. et al. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Am J Obstet Gynecol 2021; 225 (03) 278.e1-278.e16
    CrossrefPubMedGoogle Scholar
  • 21 Cobas® HPV Test: Delivering confidence with 3-in-1 HPV test results. [Internet]. Diagnostics Roche. 2022 [citado 21 de novembro de 2022]. Disponível em: https://diagnostics.roche.com/global/en/products/params/cobas-hpv.html
    PubMedGoogle Scholar
  • 22 Atualização da Nomenclatura para Laudos Citopatológicos – SBC | Sociedade Brasileira de Patologia [Internet]. 2020 [citado 29 de abril de 2023]. Disponível em: https://www.sbp.org.br/e-book-sociedade-brasileira-de-citopatologia-sbc/
    PubMedGoogle Scholar
  • 23 National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 1989; 262 (07) 931-934
    CrossrefPubMedGoogle Scholar
  • 24 Ding T, Li L, Duan R, Chen Y, Yang B, Xi M. Risk factors analysis of recurrent disease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia. Int J Gynecol Obstet [Internet]. 10 de julho de 2022 [citado 21 de novembro de 2022];n/a(n/a). Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.14340
    PubMedGoogle Scholar
  • 25 Wentzensen N, Walker J, Smith K, Gold MA, Zuna R, Massad LS. et al. A prospective study of risk-based colposcopy demonstrates improved detection of cervical precancers. Am J Obstet Gynecol 2018; 218 (06) 604.e1-604.e8
    CrossrefPubMedGoogle Scholar
  • 26 Campos-Romero A, Anderson KS, Longatto-Filho A, Esparza MAL-R, Morán-Portela DJ, Castro-Menéndez JÁ. et al. The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study. Scientific Reports 2019; 9 (01) 10
    CrossrefPubMedGoogle Scholar
  • 27 Levi JE, Martins TR, Longatto-Filho A, Cohen DD, Cury L, Fuza LM. et al. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil. Cancer Prev Res (Phila) 2019; 12 (08) 539-546
    CrossrefPubMedGoogle Scholar
  • 28 Stoler MH, Wright Jr TC, Parvu V, Yanson K, Cooper CK, Andrews J. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. Gynecol Oncol 2019; 153 (01) 26-33
    CrossrefPubMedGoogle Scholar
  • 29 Bonde JH, Sandri MT, Gary DS, Andrews JC. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis 2020; 24 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 30 Volesky KD, Magnan S, Mayrand MH, Isidean SD, El-Zein M, Comète E. et al. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening. Cancer Epidemiol Biomarkers Prev 2022; 31 (04) 851-857
    CrossrefPubMedGoogle Scholar
  • 31 Syler LB, Stobaugh CL, Foulis PR, Carlton GT, DeLand LA, Borkowski AA. Cervical Cancer Screening in South Florida Veteran Population, 2014 to 2020: Cytology and High-Risk Human Papillomavirus Correlation and Epidemiology. Cureus 2021; 13 (08) e17247
    PubMedGoogle Scholar
  • 32 Gonzalez AA, Ametorgoh A, Hamele-Bena D, Everest S, Virk R, Cimic A. et al. The significance of ASC-H and LSIL dual interpretation with risk stratification: one institution experience. J Am Soc Cytopathol 2021; 10 (06) 565-570
    CrossrefPubMedGoogle Scholar
  • 33 Ince U, Aydin O, Peker O. Clinical importance of “low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion (LSIL-H)” terminology for cervical smears 5-year analysis of the positive predictive value of LSIL-H compared with ASC-H, LSIL, and HSIL in the detection of high-grade cervical lesions with a review of the literature. Gynecol Oncol 2011; 121 (01) 152-156
    CrossrefPubMedGoogle Scholar
  • 34 Hanley SJB, Fujita H, Aoyama-Kikawa S, Kasamo M, Torigoe T, Matsuno Y. et al; COMPACT study group. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study. J Gynecol Oncol 2021; 32 (06) e86
    CrossrefPubMedGoogle Scholar
  • 35 Thomsen LT, Kjaer SK, Munk C, Ørnskov D, Waldstrøm M. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. Acta Obstet Gynecol Scand 2021; 100 (03) 394-402
    CrossrefPubMedGoogle Scholar
  • 36 Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320 (07) 687-705
    CrossrefPubMedGoogle Scholar
  • 37 Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect 2020; 26 (05) 579-583
    CrossrefPubMedGoogle Scholar
  • 38 Vale DB, Silva MT, Discacciati MG, Polegatto I, Teixeira JC, Zeferino LC. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS One 2021; 16 (05) e0251688
    CrossrefPubMedGoogle Scholar